Please login to the form below
Moderna
This page shows the latest Moderna news and features for those working in and with pharma, biotech and healthcare.
BMS to explore new options for its immuno-oncology drug Opdivo
Like BMS, Merck &Co has also moved to extend the reach of its immuno-oncology drug, teaming up with Moderna Therapeutics to develop personalised cancer vaccines that would work alongside Keytruda.
Latest news
-
Merck & Co signs cancer vaccines research deal for Keytruda
The deal with Moderna Therapeutics will see it use the Cambridge, Massachusetts-based company's novel messenger RNA (mRNA)-based vaccine technology. ... Moderna's mRNA vaccine technology uses the unique mutations present in a patient's tumour to provoke
-
mRNA - message received
Shire. Eukarys. monogenic liver diseases; Wilson disease. Moderna Therapeutics. cancer; cardiovascular disease; infectious disease; metabolism. ... Valera LLC (Moderna Therapeutics). Infectious diseases. Merck &Co; Pasteur Institute. No clinical
-
AZ and Redx collaborate on genetics of cancer
Research will take place at Alderley Park site
-
AstraZeneca expands personalised drug partnership with Horizon
with nano-engineering firm Bind Therapeutics; and a collaboration to develop messenger RNA therapeutics with Moderna Therapeutics.
-
FDA to review AZ's fish oil drug Epanova
AZ has also entered research collaborations with Moderna Therapeutics, the Karolinska Institutet and Oxford Cancer Biomarkers.
More from news
Approximately 2 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Deal Watch September 2016
Deal Watch September 2016. Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up. ... up. Turning to the battle against the Zika virus, BARDA announced three more grants for vaccine development to Takeda (up
-
Deal Watch June 2016
Apart from the $200m upfront cash payment to Moderna, there were no other financials disclosed. ... licence. 230. Moderna Therapeutics/ Merck &Co. mRNA-based personalised cancer vaccines; exclusive for Keytruda combinations (discovery).
-
Deal Watch October 2015
Whilst considering nucleic acid-based approaches, it was interesting to see that mRNA company Moderna Therapeutics, which has a number of deals under its belt with AstraZeneca, Alexion and Merck &Co, ... This is Moderna's fourth venture in what it calls
-
Deal Watch table for January 2014
144. Moderna Therapeutics/ Alexion Pharmaceuticals. Exclusive discovery and development. Messenger RNA (mRNA) therapeutics in rare diseases for 10 product options.
-
Deal Watch table for October 2013
Moderna Therapeutics / DARPA. R&D grant. mRNA therapeutics for biodefence targets (discovery).
More from intelligence
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Tony de Fougerolles joins Evox Therapeutics as CEO
Prior to this, he was chief scientific officer at Moderna Therapeutics and has held the same role at Tolerx.
-
Medicxi appoints former GSK chair Moncef Slaoui
Dr Slaoui takes on the role alongside his other board positions, which include chairman of the board at Galvani Bioelectronics, and on the boards of Artisan Biosciences, Moderna Therapeutics and Sutovax.
-
MIT chief financial officer joins Moderna Therapeutics
MIT chief financial officer joins Moderna Therapeutics. Israel Ruiz to serve as audit committee chair on its board of directors. ... US-based biotech Moderna Therapeutics has appointed Israel Ruiz to its board of directors to serve as audit committee
-
PureTech Health appoints chief scientific officer
Bringing over 30 years of clinical development experience to the role, he joins from Moderna Therapeutics where he most recently served as president and chief scientific officer.
-
Dr Michael Watson appointed as president of Valera
Dr Michael Watson appointed as president of Valera. Former Sanofi Pasteur policy head joins Moderna Therapeutics firm. ... Valera, one of Moderna Therapeutics' venture companies, has appointed Dr Michael Watson as its new president.
More from appointments
Approximately 3 fully matching, plus 5 partially matching documents found.
Featured jobs
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Account Manager – Med Comms – London
-
Salary TBC
-
Scientific Director
-
Great salary and bebefits
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Senior Account Manager / Account Director
-
Great salary and bebefits
-
Senior Medical Writer
-
Great salary and bebefits
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
-
Senior Medical Writer
-
Great salary and benefits
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
-
Senior Programme Executive
-
Salary TBC
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
Subscribe to our email news alerts
PMHub
Health Unlimited
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...
Latest intelligence
- No incentive for a cure
- The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
- Why heading online for scientific meetings can yield greater HCP engagement
- Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
- The threat of antimicrobial resistance
- Why this issue is such a fundamental challenge...
Quick links
Infographics
